APP plays central roles in Alzheimer?s disease (AD) pathogenesis. It is cleaved to produce AB that is a major component of amyloid plaque observed in AD. The cleavage also produces intracellular region of APP (AICD) that, together with its interacting proteins such as Fe65, goes to nucleus where it regulates gene expression. Our recent study identified that Fe65 interacts with Teashirt (Tsh) protein, and together silence gene expression of sets of genes. We also found that expression of Fe65 and Tsh3 is decreased even in early stage of AD. Furthermore, genetic association studies identified protective alleles for TSHZ3 that encodes a gene for Tsh3 that are associated with higher expression of Tsh3. Finally, one of genes regulated by Fe65-Tsh3 is CASP4, a gene for caspase-4, a primate specific inflammatory caspase, which also show upregulation with AD progression. These results lead to our hypothesis that APP-Fe65-Tsh pathway suppresses expression of genes, such as caspase-4 and by doing so, protects against AD progression, and that disinhibition of this pathway contributes to AD pathogenesis. In the current proposal, we will test our hypothesis by using animal models. Since CASP4 is primate specific, we will introduce human caspase-4 gene into mice and reconstitute Fe65-Tshcaspase-4 pathway in rodent, and clarify its involvement in AD progression by crossing the mice with AD model mice (APP/PSEN bigenic mice). We will also cross Tshz3 heterozygotes with APP/PSEN bigenic mice to clarify protective effects of Tsh3 to progression of AD pathology. We will compare AD progression patterns in these mice with those in humans using postmortem brain samples. Through these analyses, we will identify and validate molecular pathway that is involved in AD progression, which can be a potential therapeutic target.

Public Health Relevance

Through this project, we will understand roles of risk factor and protective factor in progression of Alzheimer's disease. Based on this information, we may be able to devise new way of intervention to slow down the progression of the diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005138-29
Application #
8456129
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4)
Project Start
Project End
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
29
Fiscal Year
2013
Total Cost
$231,769
Indirect Cost
$97,386
Name
Icahn School of Medicine at Mount Sinai
Department
Type
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Soleimani, Laili; Ravona-Springer, Ramit; Heymann, Anthony et al. (2018) Depression is more strongly associated with cognition in elderly women than men with type 2 diabetes. Int Psychogeriatr :1-5
Ki?emet-Piska?, Spomenka; Babi? Leko, Mirjana; Blažekovi?, Antonela et al. (2018) Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementia. CNS Neurosci Ther 24:734-740
Audrain, Mickael; Haure-Mirande, Jean-Vianney; Wang, Minghui et al. (2018) Integrative approach to sporadic Alzheimer's disease: deficiency of TYROBP in a tauopathy mouse model reduces C1q and normalizes clinical phenotype while increasing spread and state of phosphorylation of tau. Mol Psychiatry :
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Zhu, Carolyn W; Grossman, Hillel; Neugroschl, Judith et al. (2018) A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer's disease: A pilot study. Alzheimers Dement (N Y) 4:609-616
Boban, Mirta; Babi? Leko, Mirjana; Miški?, Terezija et al. (2018) Human neuroblastoma SH-SY5Y cells treated with okadaic acid express phosphorylated high molecular weight tau-immunoreactive protein species. J Neurosci Methods :
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021
Qian, Winnie; Fischer, Corinne E; Schweizer, Tom A et al. (2018) Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease. Curr Alzheimer Res 15:187-194
Silverman, Jeremy M; Schmeidler, James (2018) Outcome age-based prediction of successful cognitive aging by total cholesterol. Alzheimers Dement 14:952-960
Gallagher, Damien; Kiss, Alex; Lanctot, Krista et al. (2018) Depression and Risk of Alzheimer Dementia: A Longitudinal Analysis to Determine Predictors of Increased Risk among Older Adults with Depression. Am J Geriatr Psychiatry 26:819-827

Showing the most recent 10 out of 555 publications